Fred Colen Healthcare News

This is selected healthcare news for Fred Colen, which is filed under People. There are 101 news items for this page. A press release filter page is also available for Fred Colen.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/11/2022 Neovasc Inc. (NVCN) Q3 2022 Earnings Call Transcript
Neovasc Inc. (NVCN) Q3 2022 Earnings Call Transcript Neovasc Inc. (NASDAQ:NVCN) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Mike Cavanaugh - Investor Relations Fred Colen - President & Chief Executive Officer Chris Clark - Chief Financial Officer Conference Call Participants David Martin - Bloom Burton Operator Good day ...
Seeking Alpha
11/11/2022 Neovasc Reducer assigned outpatient reimbursement code from CMS
... and outpatient procedures, both during the COSIRA-II clinical trial, and upon potential commercialisation in the USA,‚Au stated Neovasc president and chief executive officer Fred Colen. ‚AuOur reimbursement journey has been remarkably successful around the world. We are beginning to see broader adoption in markets where we have successfully ...
cardiovascularnews.com
9/20/2022 Neovasc Provides Corporate Update Following Clinical Data
... a patient population at least as large as our current target market and at a much earlier stage in the patient treatment cycle,‚Au commented Fred Colen, President and CEO of Neovasc. In addition to the study in Tel Aviv, there are multiple other clinical trials evaluating the Reducer in ...
Globe Newswire
9/20/2022 2022-09-20 | TSX:NVCN | Press Release | Neovasc Inc.
... a patient population at least as large as our current target market and at a much earlier stage in the patient treatment cycle,” commented Fred Colen, President and CEO of Neovasc. In addition to the study in Tel Aviv, there are multiple other clinical trials evaluating the Reducer in ...
stockhouse.com
9/20/2022 Neovasc Provides Corporate Update Following Clinical Data Release - Digital Journal
... a patient population at least as large as our current target market and at a much earlier stage in the patient treatment cycle,‚Au commented Fred Colen, President and CEO of Neovasc. In addition to the study in Tel Aviv, there are multiple other clinical trials evaluating the Reducer in ...
digitaljournal.com
9/20/2022 Neovasc Provides Corporate Update Following Clinical Data Release
... a patient population at least as large as our current target market and at a much earlier stage in the patient treatment cycle,‚Au commented Fred Colen, President and CEO of Neovasc. In addition to the study in Tel Aviv, there are multiple other clinical trials evaluating the Reducer in ...
cardiacvascularnews.com
9/20/2022 Neovasc Provides Corporate Update Following Clinical Data Release
... a patient population at least as large as our current target market and at a much earlier stage in the patient treatment cycle,‚Au commented Fred Colen, President and CEO of Neovasc. In addition to the study in Tel Aviv, there are multiple other clinical trials evaluating the Reducer in ...
newmediawire.com
7/5/2022 Neovasc Announces Direct Sales Operations in United Kingdom
... recent High-Cost Tariff Excluded Devices (HCTED) national catalogue. Hospitals can order the Reducer and bill the cost of the device directly to NHS England. Fred Colen, Neovasc President and Chief Executive Officer, said, ‚AuWe are pleased to expand our direct presence into the United Kingdom and want to thank ...
Globe Newswire
7/5/2022 Neovasc Announces Direct Sales Operations in United Kingdom
... recent High-Cost Tariff Excluded Devices (HCTED) national catalogue. Hospitals can order the Reducer and bill the cost of the device directly to NHS England. Fred Colen, Neovasc President and Chief Executive Officer, said, ‚AuWe are pleased to expand our direct presence into the United Kingdom and want to thank ...
Yahoo News
2/24/2022 Neovasc to Report Fourth Quarter and Full Year 2021
VANCOUVER, Feb. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire ‚Ai Neovasc Inc. ( NASDAQ , TSX : NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host ...
Globe Newswire
2/2/2022 Neovasc Announces Complete Dismissal of Securities Class
... was dismissed in its entirety with prejudice and without leave to amend. ‚AuFrom the beginning, we committed to vigorously defend against these allegations,‚Au said Fred Colen, Chief Executive Officer of Neovasc. ‚AuWe could not be more pleased with the Court's decision to completely dismiss this action with prejudice ...
Globe Newswire
7/27/2021 Neovasc to Report Second Quarter 2021 Financial Results on August 10, 2021
VANCOUVER, July 27, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ( NASDAQ , TSX : NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021. Neovasc's President and Chief Executive Officer, Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call ...
Globe Newswire
1/29/2021 American Medical Association Issues New CPT Code for Neovasc Reducer Procedure
... securing adequate reimbursement in the United States. ‚AuWe are pleased that the AMA has included the Reducer procedure as a Category III code,‚Au commented Fred Colen, President and CEO of Neovasc. ‚AuObtaining adequate reimbursement for Reducer is a critical component of our long-term growth strategy that will enable ...
Business Insider
1/16/2021 Neovasc Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer‚Ñ¢ Nasdaq:NVCN
... that it has received a ‚Aunot-approvable‚Au letter from U.S. Food & Drug Administration (FDA) regarding its PMA submission for the Neovasc Reducer‚N¢ (Reducer). Fred Colen, Neovasc CEO, said, ‚AuWhile we are disappointed in FDA's decision, the letter was not unexpected, given the outcome of the Panel meeting ...
Globe Newswire
1/15/2021 Neovasc Responds to FDA Not-Approvable Letter Regarding Neovasc Reducer‚Ñ¢
... that it has received a ‚Aunot-approvable‚Au letter from U.S. Food & Drug Administration (FDA) regarding its PMA submission for the Neovasc Reducer‚N¢ (Reducer). Fred Colen, Neovasc CEO, said, ‚AuWhile we are disappointed in FDA's decision, the letter was not unexpected, given the outcome of the Panel meeting ...
Business Insider
8/13/2020 Neovasc Provides Corporate Update
VANCOUVER and MINNEAPOLIS, MN, Aug. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN), today provided a corporate update on progress towards its value creation strategies. Fred Colen, Chief Executive Officer of Neovasc, commented, “We are pleased to provide a corporate update to our ...
Globe Newswire
8/7/2020 Neovasc Announces Second Quarter Financial Results
... of our novel devices to help patients with limited options for treating debilitating angina, and advancing at the forefront of mitral valve replacement technology,” said Fred Colen, Chief Executive Officer. “We continued to focus on the commercialization of the Reducer in the EU, and were pleased to see a sharp ...
Globe Newswire
8/6/2020 Neovasc Announces Second Quarter Financial Results
... of our novel devices to help patients with limited options for treating debilitating angina, and advancing at the forefront of mitral valve replacement technology,” said Fred Colen, Chief Executive Officer. “We continued to focus on the commercialization of the Reducer in the EU, and were pleased to see a sharp ...
newmediawire.com
8/6/2020 Neovasc Announces Second Quarter Financial Results
... of our novel devices to help patients with limited options for treating debilitating angina, and advancing at the forefront of mitral valve replacement technology,” said Fred Colen, Chief Executive Officer. “We continued to focus on the commercialization of the Reducer in the EU, and were pleased to see a sharp ...
wapakdailynews.com
8/6/2020 Neovasc Announces Second Quarter Financial Results
... of our novel devices to help patients with limited options for treating debilitating angina, and advancing at the forefront of mitral valve replacement technology,” said Fred Colen, Chief Executive Officer. “We continued to focus on the commercialization of the Reducer in the EU, and were pleased to see a sharp ...
gurufocus.com
7/9/2020 Neovasc Announces Circulatory System Devices Panel Meeting Date for Neovasc Reducer Device
... marks a significant milestone for Neovasc, as we continue to work closely with the FDA towards approval of the Reducer in the United States,” said Fred Colen, President and Chief Executive Officer of Neovasc. “We look forward to discussing the role that Reducer can play in alleviating the suffering that ...
newmediawire.com
7/9/2020 Neovasc Announces Circulatory System Devices Panel Meeting Date for Neovasc Reducer™ Device Nasdaq:NVCN
... marks a significant milestone for Neovasc, as we continue to work closely with the FDA towards approval of the Reducer in the United States,” said Fred Colen, President and Chief Executive Officer of Neovasc. “We look forward to discussing the role that Reducer can play in alleviating the suffering that ...
Globe Newswire
7/9/2020 Neovasc Announces Circulatory System Devices Panel Meeting Date for Neovasc Reducer Device
... marks a significant milestone for Neovasc, as we continue to work closely with the FDA towards approval of the Reducer in the United States,” said Fred Colen, President and Chief Executive Officer of Neovasc. “We look forward to discussing the role that Reducer can play in alleviating the suffering that ...
wapakdailynews.com
2/11/2020 Neovasc Initiates Independent Inquiry Into Trading of its Shares
... level playing field for all investors in Neovasc, with full, plain and prompt disclosure of material information, into a market free from trading manipulation,” commented Fred Colen, President and Chief Executive Officer of Neovasc. “We are pleased that Professor Mitts has agreed to undertake an independent review of recent past ...
Globe Newswire
1/31/2020 Neovasc Announces Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer for Treatment of Refractory Angina
... annually. In 2020, 184 German hospitals applied for the Reducer NUB status, and they can now negotiate full reimbursement coverage for the Neovasc Reducer therapy. Fred Colen, CEO of Neovasc, commented, "We are excited to continue to see significant growth in Germany with more and more hospitals getting NUB 1 ...
Globe Newswire